Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported additional 36-week and 16-week off-drug findings from Part B of its SIGNAL-AA trial of bempikibart, noting durability of response. The company said the open-label extension is ongoing, expects to begin a registration-directed program in 1H 2027 subject to regulatory discussions, and announced leadership appointments.
Why it matters — The update covers clinical findings and planned development milestones for bempikibart in alopecia areata, as well as changes to Q32 Bio’s leadership team.